AbbVie (ABBV)Officer sold ~$5.38M

~$5.38M

Approx. value · 26K sh @ $209.49

86K

Holds after · shares reported

Traded

Mar 31, 2025

Filed

Apr 2, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jan 15, 2025Congress · 1 personMembers of Congress: 2 purchases
2. Feb 7, 2025FDAFDA drug approval: Emblaveo
3. Feb 20, 2025Insider · 1 personInsiders: 2 sales (~$1.1M)
4. Feb 24, 2025CongressDisclosed purchase of ABBV — reported range $50,001 - $100,000
5. Feb 25, 2025CongressDisclosed purchase of ABBV — reported range $1,001 - $15,000
6. Feb 26, 2025Insider · 2 peopleInsiders: 8 sales (~$9.9M)
7. Feb 28, 2025Insider · 2 peopleInsiders: 4 sales (~$21.0M)
8. Mar 3, 2025Insider · 3 peopleInsiders: 5 sales (~$9.6M)
9. Mar 14, 2025InsiderCFO sold ~$3.75M of ABBV shares in the open market
10. Mar 17, 2025CongressDisclosed purchase of ABBV — reported range $1,001 - $15,000
11. Mar 31, 2025 · this disclosureInsiderOfficer sold ~$5.38M of ABBV shares in the open market

What came next

1. Mar 31, 2025InsiderOfficer sold ~$6.98M of ABBV shares in the open market
2. Apr 1, 2025CongressDisclosed purchase of ABBV — reported range $1,001 - $15,000
3. Apr 3, 2025Congress · 2 peopleMembers of Congress: 1 purchase, 1 sale
4. Apr 7, 2025CongressDisclosed purchase of ABBV — reported range $1,001 - $15,000
5. Apr 8, 2025CongressDisclosed sale of ABBV — reported range $1,001 - $15,000
6. Apr 17, 2025Congress · 2 peopleMembers of Congress: 2 sales
7. Apr 28, 2025FDAFDA drug approval: Rinvoq
8. May 5, 2025CongressDisclosed purchase of ABBV — reported range $1,001 - $15,000
9. May 14, 2025FDAFDA drug approval: Emrelis
10. May 15, 2025CongressDisclosed purchase of ABBV — reported range $1,001 - $15,000
11. May 22, 2025FDAFDA drug approval: Lupron Depot-Ped Kit
12. May 22, 2025CongressDisclosed purchase of ABBV — reported range $1,001 - $15,000
13. Jun 10, 2025FDAFDA drug approval: Mavyret
14. Jun 10, 2025FDAFDA drug approval: Mavyret

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for AbbVie

For AbbVie, OQRO holds 2 insider filings (SEC Form 4 or Form 144), 2 Congress trade reports, 130 fund holdings reports (13F) and 2 federal contract awards dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ABBV page.

Other recent filings by Jeffrey Ryan Stewart, EVP, CHIEF COMMERCIAL OFFICER

• SEC Form 4 at AbbVie (ABBV)Apr 2, 2025

The full history of Jeffrey Ryan Stewart, EVP, CHIEF COMMERCIAL OFFICER is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at AbbVie

• House Clerk periodic transaction reportSep 18, 2026
• SEC Form 13F-HRAug 26, 2026
• SEC Form 13F-HRAug 25, 2026
• SEC Form 4Aug 18, 2026
• SEC Form 13F-HRAug 17, 2026
• SEC Form 144Aug 14, 2026

Everything OQRO holds on this company is on its ABBV page.